Sellas GPS Trial Records 80th Event, Triggering Final Analysis
Sellas Life Sciences said its Phase 3 REGAL trial of galinpepimut-S recorded its 80th death, triggering the final analysis.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.